X4 Pharmaceuticals, Inc. (XFOR)

NCM – Real Time Price. Currency in USD

4.34

-0.16 (-3.56%)

At close: May 12, 2026, 4:00 PM EDT

4.40

+0.06 (1.38%)

After-hours: May 12, 2026, 7:38 PM EDT

06.05.2026

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago.

06.05.2026

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. “Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia,” said Adam Craig, M.D.

29.04.2026

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, announced today that the European Commission (EC) has granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union (EU). The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

01.04.2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.

17.03.2026

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $6.01 per share a year ago.

17.03.2026

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Adam Craig, M.D.

09.03.2026

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.

Videos

No Data

There is no data to display

Press releases

06.05.2026

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

29.04.2026

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

01.04.2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17.03.2026

X4 Pharmaceuticals, Inc. (XFOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Videos

No Data

Press releases

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Videos

No Data

Press releases

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Search stocks

X4 Pharmaceuticals, Inc. (XFOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Videos

No Data

Press releases

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Videos

No Data

Press releases

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update